William Blair research analyst Tim Lugo was quoted in this Barron’s article discussing Sarepta Therapeutics and the intersection of approvals for its new gene therapy drug and a recent decline in the stock price.
“We continue to believe that SRP-9001 represents both a meaningful therapy for patients and significant opportunity for Sarepta,” his research note said.